FDA approves HBV vaccine Heplisav-B for adults

FDA approves HBV vaccine Heplisav-B for adults Dynavax announced that the FDA approved Heplisav-B, a recombinant hepatitis B vaccine, for all known subtypes of HBV in adults aged 18 years or older, according to a press release. “Once physicians and public health institutions become aware of Heplisav-B, it will be […]